Tuesday, March 29, 2011
Probably for the better
Johnson & Johnson recently decided to cancel an upcoming clinical trial for its injectable antipsychotic, Invega Sustenna, citing a "reconsideration of priorities." Probably a smart move, considering the recalls that the company has done in the last few months for other products. Yikes! Check it out at the Wall Street Journal.